Investigational drug · Phase 3
IVA337
Also called: Lanifibranor
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NASH - Nonalcoholic Steatohepatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "IVA337"
First trial start
2021
Aug 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IVA337", any sponsor or status.
Conditions studied
As listed on its trial records.
- NASH - Nonalcoholic Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "IVA337" as an intervention, largest first.
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Pivotal-lookingActive, not recruiting
Inventiva PharmaIndustry
NCT04849728 · 1,000 participants (planned) · Start Aug 19, 2021 · Primary completion Sep 29, 2026
Drug: IVA337; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Madison, Alabama · 459 sites in all
- Phase 2b Study in NASH to Assess IVA337Pivotal-lookingCompleted
Inventiva PharmaIndustry
NCT03008070 · 247 participants · Start Feb 7, 2017 · Primary completion Feb 20, 2020
Drug: IVA337; IVA337 and 1 more · For: Non-Alcoholic Steatohepatitis (NASH)
Sites: Madison, Alabama; La Jolla, California; Los Angeles, California · 85 sites in all
- Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic SclerosisPivotal-lookingCompleted
Inventiva PharmaIndustry
NCT02503644 · 145 participants · Start Oct 29, 2015 · Primary completion Oct 2018
Drug: IVA337; Placebo · For: Scleroderma, Diffuse; Diffuse Cutaneous Systemic Sclerosis
Sites: Pleven, Bulgaria; Plovdiv, Bulgaria; Sofia, Bulgaria · 49 sites in all
- Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseasePivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT03459079 · 128 participants · Start Aug 14, 2018 · Primary completion Apr 18, 2023
Drug: Lanifibranor · For: Nonalcoholic Fatty Liver Disease (NAFLD); Type 2 Diabetes (T2DM)
Sites: Gainesville, Florida
Inventiva PharmaIndustry
NCT03866369 · 36 participants · Start Jan 17, 2019 · Primary completion Aug 27, 2019
Drug: Moxifloxacin; Placebo and 2 more · For: Healthy Subjects
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Combination pharmacotherapy for MASH: Potential synergistic approaches.
Meije DA, Holleboom AG, van de Graaf SFJ · Biochem Pharmacol 2026
- Pan-PPAR agonists: Emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease.
Guo M, Wu Q, Deng CH, et al. · Metabolism 2026
- Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF-β Axis Inhibition and Ferroptosis Induction.
Yang Y, Mu M, Ren K, et al. · Adv Healthc Mater 2026
- MASLD: Established Knowledge and Emerging Directions - Guideline Updates.
Roeb E, Geier A · Z Gastroenterol 2026
- A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
You Z, Yang L, Long Y, et al. · Front Pharmacol 2026
- Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway.
Pang J, Do LNH, Delgado E, et al. · Vascul Pharmacol 2026
Also in development for NASH - Nonalcoholic Steatohepatitis
- EfruxiferminPhase 33 trials
Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH
- efocipegtrutideHM15211Phase 21 trial
Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis
- SNP-610Phase 21 trial
Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.